[关键词]
[摘要]
摘 要 脑血管痉挛(cerebral vasospasm, CVS)是蛛网膜下腔出血(subarachnoid hemorrhage, SAH)最常见的高危并发症之一, 是SAH患者致死和致残的主要原因。有证据表明, 内皮素信号系统在SAH后CVS和迟发性脑缺血损伤的病理生理过程中起重要作用, 因而内皮素受体拮抗剂在CVS治疗中的意义备受关注。克拉生坦(Clazosentan)是一种选择性内皮素受体拮抗剂, 动物实验和临床试验都表明其可有效缓解SAH引发的CVS, 故有望成为脑血管痉挛的新型治疗药物。
[Key word]
[Abstract]
Abstract: Cerebral vasospasm (CVS) is one of the most common complications with high risk following subarachnoid hemorrhage (SAH), and a leading cause of death and disability in SAH patients. There are evidences shown that endothelin pathways play key roles in the CVS following SAH and late cerebral ischemic injury, thus the therapeutic significance of endothelin receptor antagonists in CVS attract widely attention. Clazosentan, a selective endothelin receptor antagonist, has been proved to be effective for SAH-induced CVS in animal experiments and clinical trials. It is expected to become a new drug for treatment of CVS.
[中图分类号]
[基金项目]